Literature DB >> 16217686

[Epidemiological study of prevalence, incidence and neuropathic pain characterization in neurology units. PREVADOL study].

J Montero Homs1, E Gutiérrez-Rivas, J Pardo Fernández, C Navarro Darder.   

Abstract

INTRODUCTION: Neuropathic pain is defined as a pain initiated or caused by a lesion or dysfunction in the nervous system. The objectives of the study were to estimate the prevalence and incidence of neuropathic pain in hospital neurology units and primary care centres, to characterize the clinical profile of the patient with neuropathic pain and to know the most frequent treatments in the pharmacological management of this type of pain.
METHODS: Observational, cross-sectional epidemiological survey carried out in 36 Neurology Units of the national territory (24 primary care centres and 12 hospitals). During 20 consecutive days neurologists collected the diagnoses of all the attended patients by any reason, up to 30 patients/day. In parallel the 20 first consecutive patients with neuropathic pain were chosen for their characterization in depth by means of a specific questionnaire.
RESULTS: A total of 12,688 patients were attended and a total of 13,555 diagnoses were collected through 713 consultation days. The most frequent diagnosis was migraine/cephalea, with a prevalence of 23.40% (95% CI: 22.66%-24.14%). Neuropathic pain represented the eighth more frequent diagnosis, with a prevalence in neurology units of 3.88% (95% CI: 3.54%- 4.22%). The prevalence of neuropathic pain was 2.92% in primary care centres and 6.09% in hospital units (p < 0.01). The daily incidence of new neuropathic pain cases was 1.24% (95% CI: 1.05%-1.53%); 1.14% in primary care neurology centres and 1.45% in hospital units.
CONCLUSIONS: The data obtained indicate that neuropathic pain is the eighth more frequent diagnosis in the neurology units. Medical assistance request by neuropathic pain is higher in the hospital units.

Entities:  

Mesh:

Year:  2005        PMID: 16217686

Source DB:  PubMed          Journal:  Neurologia        ISSN: 0213-4853            Impact factor:   3.109


  8 in total

1.  Post hoc analysis of pregabalin vs. non-pregabalin treatment in patients with cancer-related neuropathic pain: better pain relief, sleep and physical health.

Authors:  Ana Mańas; Juan Pablo Ciria; María Carmen Fernández; María Luisa Gonzálvez; Virginia Morillo; María Pérez; Xavier Masramon; Vanessa López-Gómez
Journal:  Clin Transl Oncol       Date:  2011-09       Impact factor: 3.405

2.  The prevalence of neuropathic pain: clinical evaluation compared with screening tools in a community population.

Authors:  Barbara P Yawn; Peter C Wollan; Toby N Weingarten; James C Watson; W Michael Hooten; L Joseph Melton
Journal:  Pain Med       Date:  2009-03-17       Impact factor: 3.750

3.  Prevalence and characterization of neuropathic pain in a primary-care setting in Spain: a cross-sectional, multicentre, observational study.

Authors:  Concepción Pérez; María Teresa Saldaña; Ana Navarro; Inma Vilardaga; Javier Rejas
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

4.  A registry of the aetiology and costs of neuropathic pain in pain clinics : results of the registry of aetiologies and costs (REC) in neuropathic pain disorders study.

Authors:  Manuel J Rodríguez; Antonio J García
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

5.  [Neuropathic pain among hospital in-patients. Analysis of Austrian hospital discharge data].

Authors:  T Dorner; B Gustorff; R Likar; K Lawrence; F Schwarz; A Rieder
Journal:  Schmerz       Date:  2009-02       Impact factor: 1.107

6.  Cost of treatment of peripheral neuropathic pain with pregabalin or gabapentin in routine clinical practice: impact of their loss of exclusivity.

Authors:  Antoni Sicras-Mainar; Javier Rejas-Gutiérrez; María Pérez-Páramo; Ruth Navarro-Artieda
Journal:  J Eval Clin Pract       Date:  2016-09-27       Impact factor: 2.431

7.  Prevalence of central and peripheral neuropathic pain in patients attending pain clinics in Spain: factors related to intensity of pain and quality of life.

Authors:  Inmaculada Failde; María Dueñas; Maria Victoria Ribera; Rafael Gálvez; Juan A Mico; Alejandro Salazar; Helena de Sola; Concepción Pérez
Journal:  J Pain Res       Date:  2018-09-12       Impact factor: 3.133

Review 8.  In Vitro and In Vivo Effects of Flavonoids on Peripheral Neuropathic Pain.

Authors:  Paramita Basu; Arpita Basu
Journal:  Molecules       Date:  2020-03-05       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.